Managing Bacterial Co-infection in Adults with Severe Ebola Virus Disease
Clinical scenario
Adult
Bacterial co-infection
Severe disease
In adults with severe Ebola virus disease, concurrent bacterial co-infection is a recognised complication that warrants a distinct management approach beyond standard supportive care.
Why bacterial co-infection matters here
Bacterial co-infection in the context of severe Ebola virus disease affects the treatment strategy directly. The suspected site of bacterial infection — and its clinical features — determines which antibiotic regimen is appropriate, requiring a structured protocol to guide the choice and combination of agents.
Treatment approach (partial)
Management centres on an intravenous antibiotic regimen, with specific agent selection and combinations based on the suspected bacterial source — the complete protocol details which agents apply under which clinical conditions.
References
- Severe disease: IV ceftriaxone 2 g once daily 5 days +/- IV metronidazole 500 mg three times/day (usually 7 days).
- If suspect bacterial meningitis, then give higher dose, ceftriaxone at 2 g twice daily.
- Adult: oral 500 mg twice daily (7–10 days for typhoid) or IV 400 mg twice daily (5 days).
View source ↗